- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Medicare Reimbursed Nearly $14M for Telemedicine Last Year
In 2014, Medicare telemedicine reimbursement totaled $13.9 million, a number that has steadily increased since 2008, according to the Robert J. Waters Center for Telehealth and eHealth Law.
In 2014, Medicare telemedicine reimbursement totaled $13.9 million, a number that has steadily increased since 2008, according to the Robert J. Waters Center for Telehealth and eHealth Law (CTeL).
CTeL says it obtained information from CMS, which revealed that the $13.9 million figure reflects payments of $12,482,270 for provider fees at the distant site (the location of the telemedicine provider) and $1,452,160 for originating site fees (the location of the patient).
Since 2001, CMS’s Medicare reimbursement for distant site services totals $51 million and $6.5 million for originating site fees, for a total of $57.6 million over 14 years, according to CTeL. In 2001, the Congressional Budget Office estimated it would cost CMS $150 million during the first 5 years to reimburse for telehealth encounters.
Read more at Healthcare Informatics: http://bit.ly/1ELxlRa
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Bustling Gene Therapy Pipeline for Neuromuscular Diseases Brings Thorny Questions to the Clinic
March 18th 2025The rapid development of gene therapy options for treating neuromuscular diseases has created new therapeutic options but also logistical hurdles and a need for complex discussions between clinicians and families.
Read More
